Liebson P R, Grandits G A, Dianzumba S, Prineas R J, Grimm R H, Neaton J D, Stamler J
Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.
Circulation. 1995 Feb 1;91(3):698-706. doi: 10.1161/01.cir.91.3.698.
Increased left ventricular mass (LVM) by echocardiography is associated with increased risk of cardiovascular disease. Thus, it is of interest to compare the effects of both pharmacological and nonpharmacological approaches to the treatment of hypertension on reduction of LVM.
Changes in LV structure were assessed by M-mode echocardiograms in a double-blind, placebo-controlled clinical trial of 844 mild hypertensive participants randomized to nutritional-hygienic (NH) intervention plus placebo or NH plus one of five classes of antihypertensive agents: (1) diuretic (chlorthalidone), (2) beta-blocker (acebutolol), (3) alpha-antagonist (doxazosin mesylate), (4) calcium antagonist (amlodipine maleate), or (5) angiotensin-converting enzyme inhibitor (enalapril maleate). Echocardiograms were performed at baseline, at 3 months, and annually for 4 years. Changes in blood pressure averaged 16/12 mm Hg in the active treatment groups and 9/9 mm Hg in the NH only group. All groups showed significant decreases (10% to 15%) in LVM from baseline that appeared at 3 months and continued for 48 months. The chlorthalidone group experienced the greatest decrease at each follow-up visit (average decrease, 34 g), although the differences from other groups were modest (average decrease among 5 other groups, 24 to 27 g). Participants randomized to NH intervention only had mean changes in LVM similar to those in the participants randomized to NH intervention plus pharmacological treatment. The greatest difference between groups was seen at 12 months, with mean decreases ranging from 35 g (chlorthalidone group) to 17 g (acebutolol group) (P = .001 comparing all groups). Within-group analysis showed that changes in weight, urinary sodium excretion, and systolic BP were moderately correlated with changes in LVM, being statistically significant in most analyses.
NH intervention with emphasis on weight loss and reduction of dietary sodium is as effective as NH intervention plus pharmacological treatment in reducing echocardiographically determined LVM, despite a smaller decrease in blood pressure in the NH intervention only group. A possible exception is that the addition of diuretic (chlorthalidone) may have a modest additional effect on reducing LVM.
超声心动图显示左心室质量(LVM)增加与心血管疾病风险增加相关。因此,比较药物和非药物治疗高血压对降低LVM的效果具有重要意义。
在一项双盲、安慰剂对照的临床试验中,对844名轻度高血压参与者进行了M型超声心动图检查,以评估左心室结构的变化。这些参与者被随机分为营养卫生(NH)干预加安慰剂组或NH加五类抗高血压药物之一的组:(1)利尿剂(氯噻酮),(2)β受体阻滞剂(醋丁洛尔),(3)α受体拮抗剂(甲磺酸多沙唑嗪),(4)钙拮抗剂(马来酸氨氯地平),或(5)血管紧张素转换酶抑制剂(马来酸依那普利)。在基线、3个月时以及之后4年每年进行超声心动图检查。积极治疗组的血压平均下降16/12 mmHg,仅接受NH干预的组血压平均下降9/9 mmHg。所有组的LVM均较基线显著下降(10%至15%),在3个月时出现并持续48个月。氯噻酮组在每次随访时下降幅度最大(平均下降34 g),尽管与其他组的差异较小(其他5组平均下降24至27 g)。仅随机接受NH干预的参与者的LVM平均变化与随机接受NH干预加药物治疗的参与者相似。组间最大差异出现在12个月时,平均下降幅度从35 g(氯噻酮组)到17 g(醋丁洛尔组)(比较所有组,P = 0.001)。组内分析表明,体重、尿钠排泄和收缩压的变化与LVM的变化中度相关,在大多数分析中具有统计学意义。
尽管仅接受NH干预的组血压下降幅度较小,但强调体重减轻和减少饮食中钠摄入的NH干预在降低超声心动图测定的LVM方面与NH干预加药物治疗同样有效。一个可能的例外是,添加利尿剂(氯噻酮)可能对降低LVM有适度的额外效果。